AU2003256988A1 - Methods and compositions for treating polycystic ovary syndrome - Google Patents
Methods and compositions for treating polycystic ovary syndromeInfo
- Publication number
- AU2003256988A1 AU2003256988A1 AU2003256988A AU2003256988A AU2003256988A1 AU 2003256988 A1 AU2003256988 A1 AU 2003256988A1 AU 2003256988 A AU2003256988 A AU 2003256988A AU 2003256988 A AU2003256988 A AU 2003256988A AU 2003256988 A1 AU2003256988 A1 AU 2003256988A1
- Authority
- AU
- Australia
- Prior art keywords
- compositions
- methods
- polycystic ovary
- ovary syndrome
- treating polycystic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/317,126 | 2002-12-11 | ||
US10/317,126 US7105489B2 (en) | 2002-01-22 | 2002-12-11 | Methods and compositions for treating polycystic ovary syndrome |
AUPCT/US2003/001109 | 2003-01-14 | ||
PCT/US2003/001109 WO2003061362A2 (fr) | 2002-01-22 | 2003-01-14 | Procedes et compositions pour le traitement du syndrome des ovaires polykystiques |
PCT/US2003/023715 WO2004052390A1 (fr) | 2002-12-11 | 2003-07-30 | Methodes et compositions de traitement du syndrome stein-leventhal |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2003256988A1 true AU2003256988A1 (en) | 2004-06-30 |
Family
ID=32926094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2003256988A Abandoned AU2003256988A1 (en) | 2002-12-11 | 2003-07-30 | Methods and compositions for treating polycystic ovary syndrome |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1581247A4 (fr) |
JP (1) | JP2006520747A (fr) |
AU (1) | AU2003256988A1 (fr) |
WO (1) | WO2004052390A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007081980A2 (fr) * | 2006-01-10 | 2007-07-19 | Diobex, Inc. | Méthodes et compositions de traitement du cancer de la prostate, de l'hypertrophie bénigne de la prostate, du syndrome des ovaires polykystiques |
ZA200902127B (en) | 2006-10-02 | 2010-07-28 | Cortendo Invest Ab | Ketoconazole enantiomer in humans |
RU2413528C2 (ru) | 2007-01-18 | 2011-03-10 | Открытое Акционерное Общество "Валента Фармацевтика" | Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения |
JP2010539049A (ja) * | 2007-09-11 | 2010-12-16 | モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト | サイモシンβ4の単独、またはセクロピンAとの組合せでの、治療剤としてのペプチドの使用 |
EP2197462A2 (fr) * | 2007-09-11 | 2010-06-23 | Mondobiotech Laboratories AG | Utilisation d'un peptide du recepteur de il-1, seule ou en combinaison avec un ester d-ala-gln-octadecyl, en tant qu'agent thérapeutique |
WO2013079560A1 (fr) | 2011-11-29 | 2013-06-06 | Westfälische Wilhelms-Universität Münster | Marqueur génétique pour le syndrome des ovaires polykystiques (sopk) |
RU2573933C1 (ru) | 2014-08-21 | 2016-01-27 | Дафот Энтерпрайсис Лимитед | Пептид для лечения сахарного диабета 2-го типа и его осложнений |
GB201518979D0 (en) * | 2015-10-27 | 2015-12-09 | Univ Leuven Kath | Treatment of hepatic steatosis related oligo-ovulation |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2247676T3 (es) * | 1997-01-07 | 2006-03-01 | Amylin Pharmaceuticals, Inc. | Uso de las exendinas y de los agonistas de las mismas para la reduccion de la ingesta alimenticia. |
BR9811866A (pt) * | 1997-08-08 | 2000-08-15 | Amylin Pharmaceuticals Inc | Compostos agonistas de exendina |
WO2000007617A1 (fr) * | 1998-07-31 | 2000-02-17 | Novo Nordisk A/S | Utilisation de glp-1 et d'analogues pour prevenir le diabete de type ii |
WO2000028991A1 (fr) * | 1998-11-13 | 2000-05-25 | Fujisawa Pharmaceutical Co., Ltd. | Remedes contre le syndrome des ovaires polykystiques |
CA2475377A1 (fr) * | 2002-02-07 | 2003-08-14 | Pfizer Inc. | Utilisation d'inhibiteurs pde5, tel que le sildenafil, dans le traitement du syndrome d'ovaire polykystique |
WO2004050115A2 (fr) * | 2002-12-03 | 2004-06-17 | Novo Nordisk A/S | Polytherapie mettant en oeuvre des exendines et des thiazolidinediones |
-
2003
- 2003-07-30 EP EP03812761A patent/EP1581247A4/fr not_active Withdrawn
- 2003-07-30 AU AU2003256988A patent/AU2003256988A1/en not_active Abandoned
- 2003-07-30 JP JP2005508433A patent/JP2006520747A/ja active Pending
- 2003-07-30 WO PCT/US2003/023715 patent/WO2004052390A1/fr active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2004052390B1 (fr) | 2004-09-10 |
EP1581247A1 (fr) | 2005-10-05 |
EP1581247A4 (fr) | 2007-09-12 |
WO2004052390A1 (fr) | 2004-06-24 |
JP2006520747A (ja) | 2006-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003262747A1 (en) | Compounds, compositions, and methods | |
AU2003236527A1 (en) | Compounds, compositions, and methods | |
AU2003265242A1 (en) | Compounds, compositions, and methods | |
AU2003219942A1 (en) | Composition and process for well cleaning | |
AU2003270015A1 (en) | Compounds, compositions, and methods | |
AU2003230750A1 (en) | Compositions and methods for treating cancer | |
AU2003247624A1 (en) | Method of treating the syndrome of lipodystrophy | |
AU2003299612A1 (en) | Compounds, compositions and methods | |
AU2003256805A1 (en) | Compounds compositions and methods | |
AU2003225535A1 (en) | Methods and compositions for treating cancer | |
AU2003212894A1 (en) | Compositions and methods for treating diarrhea | |
AUPS236902A0 (en) | Composition and method for treating hypertension | |
AU2003297573A1 (en) | Compositions and methods for treating transplants | |
AU2003266815A1 (en) | Immunoglobulin compositions and methods | |
AU2003225104A1 (en) | Composition for reducing malodors and method for using the same | |
AU2003290507A1 (en) | Compounds, compositions and methods | |
AU2003277079A1 (en) | Compounds, compositions, and methods | |
AU2003296963A1 (en) | Methods and compositions for treating and preventing ear infections | |
AU2003256988A1 (en) | Methods and compositions for treating polycystic ovary syndrome | |
AU2003213048A1 (en) | Composition and method for protecting labile active components | |
AU2003238905A1 (en) | Surface treating compositions and methods for using same | |
AU2003259202A1 (en) | Compositions and methods for treating and preventing infection | |
AU2003295574A1 (en) | Method and compositions for temporarily incapaciting subjets | |
AU2003300031A1 (en) | Compounds, compositions, and methods | |
AU2003267169A1 (en) | Compounds, compositions and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |